Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | SDHA | P31040 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CALML3 | P27482 | 1/20 | 0.64 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217993 | 0.92 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16204406 | 0.84 | MAOA (0.83) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6979510 | 0.84 | MAOA (0.83) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6988071 | 0.84 | MAOA (0.83) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1668751 | 0.84 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5725703 | 0.84 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4634029 | 0.83 | MAOA (0.63) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4634026 | 0.83 | MAOA (0.63) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701350 | 0.83 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701349 | 0.83 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246810-B1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO MCNEIL PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1594852-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069816-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-19 | — | — | WO | disclosed |
| US-6518285-B2 | 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1246810-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001046164-A1 | PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103377-A1 | Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials | OXA1L, RPS27L, RPS27 | MAOA 2599/4885MAOB 2107/4885PTGS1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.